https://www.prnewswire.com/news-releases/amphix-bio-receives-fda-orphan-drug-designation-for-neural-regeneration-therapeutic-to-treat-acute-spinal-cord-injury-302506799.html
Amphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute...
/PRNewswire/ -- Amphix Bio, a pre-clinical stage company developing a new therapeutic modality for regenerative medicine, received an Orphan Drug Designation...